Breast cancer
Results
Phase 2
This trial looked at a drug called AZD4547 alongside anastrozole or letrozole for breast cancer that got worse despite hormone therapy. It was for women with oestrogen receptor positive (ER positive) breast cancer.
means that the breast cancer cells are sensitive to the female hormone oestrogen.
This trial was supported by Cancer Research UK.
Recruitment start: 23 July 2012
Recruitment end: 31 December 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Michael Seckl
AstraZeneca
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Imperial College London
NIHR Clinical Research Network: Cancer
Last reviewed: 28 September 2017
CRUK internal database number: 5409
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
